Search

Displaying results 4411 - 4420 of 5261 in total
  1. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to mill...

  2. Drug

    Tonapofylline

    go.drugbank.com/drugs/DB12569
    Investigational

    Tonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.

  3. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

  4. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...

  5. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...

  6. Drug

    Nelotanserin

    go.drugbank.com/drugs/DB12555
    Investigational

    Nelotanserin works through a mechanism of action that is different from currently marketed drugs.

  7. Drug

    6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one

    go.drugbank.com/drugs/DB08267
    Experimental

    Stilbenes (C6-C2-C6) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.

  8. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  9. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

  10. Drug

    Tulathromycin A

    go.drugbank.com/drugs/DB11474
    ExperimentalVet approved

    It is marketed by Pfizer Inc. under the tradename Draxxin.